Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Deciphera Pharmaceuticals
Deciphera Pharmaceuticals
(DCPH)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Quarterly sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Qinlock
Ripretinib
2020-05-15
2030-2042
Gastrointestinal stromal tumors
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Ripretinib
neoplasms
,
systemic mastocytosis
,
mastocytosis
,
gastrointestinal stromal tumors
Sapablursen
polycythemia vera
REBASTINIB
leukemia
,
bcr-abl positive chronic myelogenous leukemia
,
adenocarcinoma
,
breast neoplasms
,
neoplasms
,
neoplasm metastasis
,
ovarian neoplasms
,
endometrial neoplasms
,
mesodermal mixed tumor
Vimseltinib
healthy volunteers/patients
,
neoplasms
,
liver diseases
,
fibrosis
,
respiratory tract diseases
,
graft vs host disease
,
immune system diseases
,
lung diseases
,
bronchiolitis obliterans
,
bronchial diseases
,
obstructive lung diseases
,
bronchiolitis
,
sclerosis
,
bronchiolitis obliterans syndrome
,
organizing pneumonia
,
giant cell tumor of tendon sheath
,
pigmented villonodular synovitis
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use